Insilico Medicine, Inc and Liquid AI have forged a strategic partnership to integrate advanced artificial intelligence tools into drug discovery workflows, according to the companies’ joint announcement. The collaboration will focus on developing lightweight scientific foundation models designed to process and interpret biological and chemical data more efficiently for research and pharmaceutical applications.
Under the agreement, the partners plan to co‑create AI models tailored to drug discovery challenges, including molecular representation, structure prediction and biological activity forecasting. These models are intended to support scientists by providing rapid insights into complex datasets, potentially shortening timelines for target identification, compound design and preclinical evaluation.
Insilico Medicine, known for its AI‑driven discovery platforms, will contribute domain expertise in biology, chemistry and therapeutic development, while Liquid AI brings engineering capabilities in efficient machine learning architectures and scalable model deployment. Together the companies aim to produce tools that offer high performance with lower computational cost.
The partnership reflects growing adoption of AI in life sciences, where foundation models trained on large‑scale scientific data can enhance hypothesis generation, improve predictive accuracy and help navigate multi‑modal information across genetic, proteomic and small‑molecule spaces. Insilico Medicine and Liquid AI said the resulting models will be accessible to researchers beyond their organisations, supporting broader innovation in drug discovery and development.
Both companies expect initial outputs from their collaboration to be available in the coming months, with plans to iterate on model performance and expand applications across therapeutic areas.
